citral has been researched along with Invasiveness, Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullah, R; Abu, N; Alitheen, NB; Masarudin, MJ; Mohamad, NE; Nordin, N; Rahman, HS; Yeap, SK; Zamberi, NR | 1 |
| Abdullah, R; Abu, N; Alitheen, NB; How, CW; Masarudin, MJ; Mohamad, NE; Nordin, N; Rahman, HS; Yeap, SK; Zamberi, NR | 1 |
2 other study(ies) available for citral and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model.
Topics: Acyclic Monoterpenes; Animals; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Carriers; Female; Humans; Lipids; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasm Invasiveness; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells.
Topics: Acyclic Monoterpenes; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 8; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Humans; Lipids; Mice; Nanostructures; Neoplasm Invasiveness | 2019 |